Clinical Trials Browser

Phase 1/2 × N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide × Clear all

NCT06235801 2026-06-02

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Myeloid